NO20063000L - Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav. - Google Patents

Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.

Info

Publication number
NO20063000L
NO20063000L NO20063000A NO20063000A NO20063000L NO 20063000 L NO20063000 L NO 20063000L NO 20063000 A NO20063000 A NO 20063000A NO 20063000 A NO20063000 A NO 20063000A NO 20063000 L NO20063000 L NO 20063000L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
combination
pharmaceutical composition
pharmaceutical
Prior art date
Application number
NO20063000A
Other languages
English (en)
Other versions
NO326958B1 (no
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063000(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Publication of NO20063000L publication Critical patent/NO20063000L/no
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO326958B1 publication Critical patent/NO326958B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20063000A 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav. NO326958B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (2)

Publication Number Publication Date
NO20063000L true NO20063000L (no) 1999-12-17
NO326958B1 NO326958B1 (no) 2009-03-23

Family

ID=26311745

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
NO20063000A NO326958B1 (no) 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav.
NO2008003C NO2008003I2 (no) 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid
NO20090846A NO20090846L (no) 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2008003C NO2008003I2 (no) 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid
NO20090846A NO20090846L (no) 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Country Status (39)

Country Link
US (3) US20060100247A1 (no)
EP (2) EP0996444B1 (no)
JP (1) JP2002504137A (no)
KR (2) KR100666591B1 (no)
CN (2) CN1114404C (no)
AP (1) AP1279A (no)
AR (2) AR012998A1 (no)
AT (1) ATE355840T1 (no)
AU (1) AU8539398A (no)
BG (2) BG109398A (no)
BR (1) BR9810172A (no)
CA (1) CA2294582C (no)
CY (2) CY1107643T1 (no)
CZ (1) CZ298469B6 (no)
DE (2) DE69837261T2 (no)
DK (1) DK0996444T3 (no)
DZ (1) DZ2520A1 (no)
EA (1) EA003144B1 (no)
ES (1) ES2284212T3 (no)
HK (1) HK1028193A1 (no)
ID (1) ID23372A (no)
IL (3) IL133142A0 (no)
IN (1) IN189722B (no)
LU (1) LU91356I2 (no)
MA (1) MA26512A1 (no)
MY (1) MY129897A (no)
NL (1) NL300288I2 (no)
NO (4) NO324993B1 (no)
NZ (1) NZ501260A (no)
OA (1) OA11516A (no)
PE (1) PE83199A1 (no)
PL (2) PL195136B1 (no)
PT (1) PT996444E (no)
SI (1) SI0996444T1 (no)
SK (1) SK286029B6 (no)
TR (1) TR199903057T2 (no)
TW (1) TW565449B (no)
UY (1) UY25049A1 (no)
WO (1) WO1998057634A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
PT974356E (pt) 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
ES2290130T3 (es) * 2000-05-01 2008-02-16 Aeropharm Technology, Llc Formulacion de nucleo.
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CA2725833A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1772149A1 (en) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
CN105152919A (zh) * 2008-07-28 2015-12-16 赛丹思科大学 用于治疗代谢疾病的化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
DE69522718T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
NZ501260A (en) 2002-09-27
EP0996444A1 (en) 2000-05-03
IL173650A0 (en) 2006-07-05
KR20060105005A (ko) 2006-10-09
IL133142A0 (en) 2001-03-19
PE83199A1 (es) 1999-10-22
AU8539398A (en) 1999-01-04
NL300288I2 (nl) 2009-06-02
TW565449B (en) 2003-12-11
AR012995A1 (es) 2000-11-22
EA003144B1 (ru) 2003-02-27
PL195140B1 (pl) 2007-08-31
JP2002504137A (ja) 2002-02-05
ES2284212T3 (es) 2007-11-01
SK179299A3 (en) 2000-11-07
CZ9904578A3 (en) 2001-06-13
OA11516A (en) 2004-02-04
BG104060A (en) 2000-10-31
CY2007018I1 (el) 2012-01-25
BG109398A (bg) 2006-05-31
EA200000041A1 (ru) 2000-08-28
US20060100247A1 (en) 2006-05-11
ID23372A (id) 2000-04-20
PL195136B1 (pl) 2007-08-31
WO1998057634A1 (en) 1998-12-23
IL133142A (en) 2006-06-11
AR012998A1 (es) 2000-11-22
US20080090881A1 (en) 2008-04-17
LU91356I2 (fr) 2008-01-29
SK286029B6 (sk) 2008-01-07
NO996266D0 (no) 1999-12-17
DK0996444T3 (da) 2007-07-02
US20070004780A1 (en) 2007-01-04
NO2008003I1 (no) 2008-04-21
SI0996444T1 (sl) 2007-08-31
CZ298469B6 (cs) 2007-10-10
BG64818B1 (bg) 2006-05-31
EP0996444B1 (en) 2007-03-07
MA26512A1 (fr) 2004-12-20
PT996444E (pt) 2007-06-08
KR20010013844A (ko) 2001-02-26
DZ2520A1 (fr) 2003-02-01
EP1787646A2 (en) 2007-05-23
NO2008003I2 (no) 2010-06-28
DE122007000054I1 (de) 2007-12-13
DE69837261T2 (de) 2007-11-08
NO996266L (no) 1999-12-17
NO20090846L (no) 1999-12-17
KR100666591B1 (ko) 2007-01-11
ATE355840T1 (de) 2007-03-15
NO326958B1 (no) 2009-03-23
EP1787646A3 (en) 2007-10-03
PL337362A1 (en) 2000-08-14
MY129897A (en) 2007-05-31
DE69837261D1 (de) 2007-04-19
CN1260716A (zh) 2000-07-19
TR199903057T2 (xx) 2000-04-21
UY25049A1 (es) 2000-09-29
CA2294582A1 (en) 1998-12-23
IN189722B (no) 2003-04-19
CN1429551A (zh) 2003-07-16
BR9810172A (pt) 2000-08-08
NO324993B1 (no) 2008-01-14
NL300288I1 (nl) 2007-11-01
CN1230171C (zh) 2005-12-07
AP9901719A0 (en) 1999-12-31
CN1114404C (zh) 2003-07-16
CA2294582C (en) 2008-02-12
CY1107643T1 (el) 2012-01-25
AP1279A (en) 2004-05-20
HK1028193A1 (en) 2001-02-09

Similar Documents

Publication Publication Date Title
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
NL300258I1 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van diabetes.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
BR9713237B1 (pt) comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
NO20003254L (no) Anti-østrogeniske steroider og farmasøytisk preparat inneholdende samme, samt anvendelse derav
DE69018647D1 (de) Arzneimittel.
DE68912237D1 (de) Dampfsensitive Zusammensetzung sowie diese enthaltende sterilisierungsanzeigende Zusammensetzung.
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
FI973475A (fi) Koostumus ja sitä sisältävä tuote
ATE97570T1 (de) Arzneimittel zur verhuetung von sexuell uebertragbaren krankheiten.
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO20011409D0 (no) Farmasøytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
DE3879811T2 (de) Pharmazeutische Zusammensetzung und ihre Verwendung.
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
NO20003229D0 (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske legemidler for behandling av proliferaktive sykdommer
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
DE68909501D1 (de) Hydroxyalkylcystein-derivate und diese enthaltende expectoranzien.
DE3850433T2 (de) Allergiebehandlung und Zusammensetzung dafür.
BR9709406B1 (pt) fluorenonas alquiloxiamino substituìdas e composição farmacêutica contendo as mesmas.
NO308251B1 (no) Karbohydratderivater, farmasøytisk blanding inneholdende karbohydratderivater samt anvendelse av samme
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees